Myasthenia gravis: recognition of a human autoantigen at the molecular level.
The symptoms of myasthenia gravis are primarily or exclusively due to an autoimmune response against the muscle nicotinic acetylcholine receptor (AChR) and this has been the object of intensive investigations for almost 20 years. A detailed picture at the molecular level of the interaction of this autoantigen with the key elements involved in the autoimmune response, such as anti-AChR antibodies, the T-cell receptor and restricting major histocompatibility complex molecules, is now emerging for both human myasthenia gravis and its experimental model, experimental autoimmune myasthenia gravis. Here, Maria Pia Protti and colleagues focus on the molecular interactions occurring in human myasthenia gravis and summarize recent information on pathogenic mechanisms of the autoimmune response, and the structure of epitopes recognized by B cells and CD4+ T cells of myasthenic patients on the AChR molecule.
Protti
M P
MP
Medicina II Department, Scientific Institute San Raffaele, Milano, Italy.
Manfredi
A A
AA
Horton
R M
RM
Bellone
M
M
Conti-Tronconi
B M
BM
D000818:Animals; D001324:Autoantigens; D006801:Humans; D007165:Immunosuppression Therapy; D009132:Muscles / Q000276:immunology; D009157:Myasthenia Gravis / Q000276:immunology* / Q000628:therapy; D011978:Receptors, Nicotinic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D001324:Autoantigens; D011978:Receptors, Nicotinic